Clinical trials: Stereotactic Body Radiation Therapy
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced…
- Trial name
- NCT06359275
- Testing
- PD-1, Nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Fudan University
Advanced Solid Tumor, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors.
- Conditions
- Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor, Safety
- Trial name
- SCARCE (NCT05915481)
- Testing
- Cadonilimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Oligometastatic Disease, Prostate Cancer
Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma
The purpose of this study is to evaluate the outcomes of patients treated with an high dose radiation regimen using either stereotactic hypofractionated or normofractionated radiotherapy for oligometastatic prostate cancer and to…
- Trial name
- Oli-P (NCT02264379)
- Testing
- normal fractionated irradiation, hypo fractionated irradiation
- Where
- 2 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Technische Universität Dresden
Breast Cancer, Recurrent Breast Cancer
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor
- Trial name
- CLEAR (NCT03750396)
- Testing
- Surgical resection, Stereotactic body radiotherapy, Radiofrequency ablation
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Gangnam Severance Hospital
Lung Cancer, Lung Metastases
Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy in Lung Cancer
The role of radiotherapy is well established in the management of early stage lung cancer or as part of a multidisciplinary approach of locally advanced lung cancer (1).
- Conditions
- Lung Cancer, Lung Metastases, Radiotherapy
- Trial name
- NCT04684186
- Testing
- Endovascular fiducial marker insertion, Bronchoscopic fiducial marker insertion
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Solid Tumor, Adult
Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases (IMPRESS)
A prospective study evaluating prone and supine positioning for radiation planning of spine Cyberknife radiotherapy treatment. Patients with tumours in which PTV coverage is compromised due to tumour geography, including…
- Trial name
- IMPRESS (NCT05252975)
- Testing
- Setup and Imaging for at CT radiation planning
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Adenocarcinoma
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the…
- Trial name
- LDR BURST (NCT07210502)
- Testing
- 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Metastatic Malignant Neoplasm in the Brain
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases.
- Trial name
- NCT02798029
- Testing
- Frameless Fractionated Stereotactic Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
This is an open label, prospective, single center Phase II clinical study. Intended to evaluate the main pathological response rate (MPR) and safety of stereotactic immunosensitized radiotherapy combined with Evoximab…
- Trial name
- NCT06391008
- Testing
- Stereotactic radiotherapy, Evoximab, Pemetrexed
- Volunteers
- 44 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Tumor
Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer
The purpose of this study is to see if SBRT will be a better way to treat pancreas cancer and to find out what effects, good and/or bad, this treatment will have on participants and their cancer.
- Trial name
- NCT01434550
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Tissue, Blood, Research Imaging (TBRI)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
This phase II trial compares the use of 225Ac-PSMA-617 to 177Lu-PSMA-617, along with stereotactic body radiotherapy for the treatment of prostate cancer that has come back after a period of improvement (recurrent) and that has…
- Trial name
- ANDROMEDA (NCT07150715)
- Testing
- Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Early Lung Cancer, Stereotactic Body Radiotherapy
Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer.
- Trial name
- USBRT-1 (NCT05802654)
- Testing
- SBRT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00547339
- Testing
- stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
Perfusion CT Imaging in Lung Cancer With SBRT
The goal of this study is to determine specific perfusion patterns for radiation induced lung changes and residual/recurrent lung malignancies in patients treated with stereotactic body radiotherapy SBRT and thus improve to…
- Trial name
- NCT02755454
- Testing
- Perfusion CT Imaging
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma
Efficacy and Safety of T+A+RAD in HCC
This is An Open-label, Single-arm Exploratory Study to determine the efficacy and safety of Multifocal Stereotactic Radiotherapy Combined with Atezolizumab and Bevacizumab in the Treatment of Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05396937
- Testing
- Multifocal Stereotactic Radiotherapy, Atezolizumab Injection [Tecentriq], Bevacizumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Recurrent High Grade Glioma
Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma
The study is aimed to evaluate efficacy and safety of re-irradiation for patients with recurrent high grade gliomas after other treatment.
- Trial name
- NCT02567539
- Testing
- IMRT with or without radiosensitive therapy, Radiosensitive therapy
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Istituto Clinico Humanitas
Neoplasms, Secondary Malignant Neoplasm
Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy
Recently, MD Anderson Cancer Center reported the phase II trial to investigate high-dose radiotherapy (HDRT, 20-70 Gy) and low-dose radiotherapy (LDRT, 1-10 Gy) for metastatic cancer patients who had undergone immunotherapy.
- Trial name
- KROG22-11 (NCT05733156)
- Testing
- SBRT + LDRT
- Where
- 2 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- Soonchunhyang University Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC)
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Nivolumab is an antibody (a type of human protein) that is designed to boost your body's immune system. It does this by allowing immune cells to grow and fight the cancer.
- Trial name
- NCT02684253
- Testing
- Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Early Stage Non-Small Cell Lung Cancer
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT03050554
- Testing
- Avelumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Andrew Sharabi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.